Occuity wins grant for optical diabetes screening device

MedTechInvestmentMedTech start-up Occuity has received a £343,000 Innovate UK Biomedical Catalyst (BMC) award to fund the next stage of development of its optical diabetes screening device.

Reading is developing the AGE reader, a medical device that will enable non-invasive diabetes screening in non-clinical settings such as ophthalmologists and pharmacies.

Biomedical Catalyst is the leading Innovate UK grant funding competition to support UK healthcare and life sciences SMEs. It supports the development of innovative solutions to health and healthcare challenges by providing financial support to accelerate the path to commercialization.

With type 2 diabetes affecting 422 million people worldwide, the costs associated with diabetes-related complications to global health services are around 10% of all government health spending – unsustainable to the point that the WHO now classify diabetes as a pandemic.

Early diagnosis is vital to enable prevention and control of diabetes and pre-diabetes when it is relatively inexpensive with treatments such as healthier diets and increased physical activity. Although the International Diabetes Foundation recommends extensive screening of older people, type 2 diabetes is increasing in younger adults and children, demonstrating the need for extensive diabetes screening.

However, current techniques require an inconvenient blood test that can only be performed in a clinical setting. This means that many people do not get tested until they have full symptoms of diabetes with their GP and/or are diagnosed as obese. Those who do not suspect problems may never be tested.

To address this need, Occuity designed an AGE reader based on research demonstrating that the concentration of advanced glycation end products (AGEs) within the eye correlates with blood glucose levels and therefore risk. of diabetes.

The AGE reader will be a non-contact handheld device that shines a blue light into the eye to illuminate the ocular lens and the returned fluorescent and diffused light from AGEs will be detected and AGE levels and diabetes risk determined.

HealthTech Founders Confirmed for Major Conference

It claims to be cheaper and faster than competitors and does not require blood draws or patient fasting. It can also be used in a non-clinical setting, making it ideal for use in pharmacies, opticians or home environments such as nursing homes.

Along with machine learning techniques, the device’s readings will aim to diagnose whether the subject is non-diabetic, pre-diabetic or diabetic.

“The value of a more convenient way to track diabetes is clear,” said Dan Daly, CEO and co-founder. “For individuals, early identification can help them take appropriate measures to avoid the worst effects of the disease, while for health services, alongside the improvement of results and the patient’s quality of life, there is a financial incentive additional.

“This grant will allow us to develop a benchtop device to demonstrate technical advances and make a functional meter to provide a route to a commercially viable product.”

Samana Brannigan, Head of Health Technologies at Innovate UK, said: “The Biomedical Catalyst funding will support Occuity on its journey to commercialize and scale up this cutting-edge technology and deliver further growth for the UK life sciences sector.

“Developing a wearable, wearable, non-invasive device for use in non-clinical settings can contribute to proactive, person-centered care in the community and lead to significant global opportunities.”

The project will start on December 1, 2022 and is projected to last 15 months. Advances in Occuity’s technology will also provide a platform for the development of other screening devices to examine other biomarkers in the eye, such as amyloid plaques, known as evidence of the presence of Alzheimer’s disease.

Diabetes startup Occuity rejuvenates the lead designer behind the iPhone

Occuity wins grant for optical diabetes screening device

Leave a Reply

Your email address will not be published.

Scroll to top